

WHAT IS CLAIMED IS:

1. A method of diagnosing or evaluating a skin injury or condition affecting the skin, said method comprising evaluating expression of:
 - 5 a) a chemokine selected from MCP-2 (CCL8), DC-CK1 (CCL18), TARC (CCL17), RANTES (CCL5), MIP3b (CCL19), I-309 (CCL1), MIG (CXCL9), IP-10 (CXCL10), ITAC (CXCL11), BCA-1 (CXCL13), lymphotactin (XCL1), MDC (CCL22), IL-8 (CXCL8), MCP-3 (CCL7), SDF-1, or MCP-1 (CCL2); or
 - 10 b) a chemokine receptor selected from CCR5, CCR7, CXCR3, CXCR5, XCR1, CCR2, CCR4, CCR8, or CXCR4.
2. The method of Claim 1, wherein said condition is selected from lupus erythematosus, atopic dermatitis, cutaneous wound, skin healing, or
15 an inflammatory condition.
3. The method of Claim 1, wherein said evaluating is:
 - a) measuring a plurality of said expression levels;
 - b) measuring mRNA levels; or
 - 20 c) measuring protein levels.
4. A method of treating a condition affecting the skin, said method comprising administering an antagonist of:
 - 25 a) a chemokine selected from MCP-2 (CCL8), DC-CK1 (CCL18), TARC (CCL17), RANTES (CCL5), MIP3b (CCL19), I-309 (CCL1), MIG (CCL9), IP-10 (CXCL10), ITAC (CXCL11), BCA-1 (CXCL13), lymphotactin (XCL1), MDC (CCL22), IL-8 (CXCL8), MCP-3 (CCL7), or MCP-1 (CCL2); or
 - 30 b) a chemokine receptor selected from CCR5, CCR7, CXCR3, CXCR5, XCR1, CCR2, CCR4, CCR8, or CXCR4.
5. The method of Claim 4, wherein said administering is:
 - a) a plurality of said antagonists; or
 - b) in combination with another therapeutic.

6. The method of Claim 4, wherein said antagonist is an antibody which prevents interaction of:

- a) said chemokine with its receptor, or
- b) said chemokine receptor with its ligand.

5

7. The method of Claim 4, wherein said treating is preventative.

8. The method of Claim 4, wherein said condition is lupus erythematosus, and said antagonist is of:

- 10 a) a chemokine selected from MCP-2 (CCL8), RANTES (CCL5), MIP3b (CCL19), MIG (CXCL9), IP-10 (CXCL10); ITAC (CXCL11); BCA-1 (CXCL13), or lymphotactin (XCL1); or
- b) a chemokine receptor selected from CCR5, CCR7, CXCR3, CXCR5, or XCR1.

15

9. The method of Claim 4, wherein said condition is atopic dermatitis, and said antagonist is of:

- a) a chemokine selected from DC-CK1 (CCL18), TARC (CCL17), I-309 (CCL1), MDC (CCL22), IP-10 (CXCL10), MIG (CXCL9), or ITAC (CXCL11); or
- 20 b) a CCR2, CCR3, CCR4, or CCR8 chemokine receptor.

25

10. A method of accelerating wound healing comprising administering to an individual suffering from a wound a chemokine selected from lymphotactin (XCL1), IL-8 (CXCL8), MCP3 (CCL7), MCP1 (CCL2), MCP-2 (CCL8), RANTES (CCL5), MIG (CXCL9), or SDF-1.

30

11. The method Claim 8, wherein said administering is:

- a) a plurality of said chemokines;
- b) in combination with another therapeutic; or
- c) by expression of a nucleic acid.

35

12. The method of Claim 8, wherein said healing is from skin loss from burn.